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wortic stiffness has been identified as an important predictor
f cardiovascular outcome independent of and additive to
raditional cardiovascular risk factors in different patient
opulations including patients with hypertension (1), dia-
etes (2), and end-stage renal disease (3), and in elderly
ospitalized subjects (4). More recently, the prognostic
ignificance of increased aortic stiffness has also been dem-
nstrated in the general population (5). The adverse effects
f elevated aortic stiffness are thought to be caused by a
remature return of reflected pressure waves in late systole,
hich increases central pressure and thus systolic blood
ressure. Increased systolic blood pressure, in turn, increases
he load on the left ventricle, inducing left ventricular
ypertrophy, increasing myocardial oxygen demand, and
ausing subendocardial ischemia. In addition to the effects
n the heart, increased aortic stiffness has been associated
ith an increase in the risk of stroke. Elevated aortic
tiffness is not confined to aging or atherosclerotic diseases
ut has also been reported in noncardiovascular disorders
uch as generalized inflammatory diseases like rheumatoid
rthritis (6) or genetic disorders such as the Marfan syn-
rome (7). Interestingly, there have been no reports so far
nvestigating aortic stiffness in patients with hypertrophic
ardiomyopathy (HCM).
See page 255
The report of Boonyasirinant et al. (8) in this issue of the
ournal is an important contribution to fill this gap in
nowledge. Aortic stiffness was determined in 100 HCM
atients and compared with that in 35 control subjects
easuring aortic pulse wave velocity (PWV) with velocity-
ncoded cardiac magnetic resonance (CMR). Remarkably,
he authors observed an increased aortic stiffness in patients
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiology, University Hospital Aachen, Aachen,m
ermany. Dr. Kühl is currently affiliated with the Klinik für Kardiologie, Klinikum
arlaching, München, Germany.ith HCM compared with healthy control subjects. There
ere no differences in age, sex, body surface area, or blood
ressure between patients and control subjects, factors
nown to affect PWV measurements. In addition, aortic
imensions were similar in both groups. Yet, PWV was
.72  5.83 m/s in patients and 3.74  0.86 m/s in control
ubjects, a highly significant difference (p  0.001). Fur-
hermore, the authors made another intriguing observation:
n the group of patients with HCM, those demonstrating
yocardial fibrosis at late gadolinium-enhanced CMR re-
ealed increased PWV compared with HCM patients with-
ut myocardial fibrosis (9.66  6.43 m/s vs. 6.51  3.25
/s, respectively; p  0.005). Regrettably, no data are
resented on the relationship between the extent of myo-
ardial fibrosis and PWV.
What is the link between HCM, myocardial fibrosis, and
ncreased stiffness of the aorta? The paper by Boonyasirinant
t al. (8) fails to give a definite answer to this question. Since
ncreased aortic stiffness has been associated with structural
hanges of the arterial wall with rearrangement of its
-dimensional architecture (9) and HCM is a disorder
haracterized by the disorganization of myocardial fiber
rchitecture, it is tempting to speculate that the structural
hanges in the myocardium and the aortic wall may have a
ommon pathway reflecting different phenotypic character-
stics of the same disease. What is more, arterial stiffness
ay have a genetic component that is largely independent of
he influence of traditional cardiovascular risk factors (9).
imilarly, HCM is a genetic disorder, which may
trengthen the argument for a common pathophysiology of
he myocardial and the aortic disease. Another potential
xplanation is that increased aortic stiffness is the sequel of
n atherosclerotic process, which is not infrequently found
n patients with HCM. These are interesting questions that
wait further clarification.
In HCM, stiffening of the aorta may impose an addi-
ional burden on an already stiff ventricle. This may have
mportant implications for ventricular-arterial coupling,
hich is the central determinant of left ventricular perfor-
ance and cardiac energetics. Modulation of cardiac per-
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HCM and MRI July 14, 2009:263–4ormance by the arterial system may affect stroke work and
nergy efficiency (i.e., the energy consumed by the heart to
chieve the required stroke work, at rest and during exer-
ise). It is likely that aortic stiffening may adversely affect
ardiac performance in HCM patients especially during
xercise. Thus, focusing exclusively on the heart may not be
ufficient to completely understand the complex pathophys-
ology of HCM.
An important question that will have to be addressed in
he future is whether the finding of an increased aortic
tiffness in HCM patients is a marker of a worse prognosis
kin to subjects with hypertension, atherosclerosis, diabetes
ellitus, or end-stage renal disease. Since in HCM patients
he finding of myocardial fibrosis at delayed enhanced CMR
as been suggested as a marker of sudden cardiac death (10),
t is tempting to speculate that excessive aortic stiffness may
lso be associated with worse prognosis in these patients.
et, the relative contribution of myocardial fibrosis and
ortic stiffness to outcome in HCM patients needs to be
lucidated in larger studies.
Increased aortic stiffness has been shown to be amenable to
harmacological treatment. For example, in Marfan patients,
reatment with angiotensin-converting enzyme inhibitors has
een reported to reverse increased aortic stiffness as well as
ortic diameter (7). Likewise, in patients with rheumatoid
rthritis, statin therapy has been shown to reduce elevated
ortic stiffness (6). In HCM patients the effects of angiotensin-
onverting enzyme inhibition on cardiac performance and
oronary flow have been discussed controversially (11). Not-
ithstanding, it will be important to investigate whether aortic
tiffness can be influenced by pharmacological treatment or
onpharmacological interventions (i.e., septal ablation, myec-
omy) in HCM patients and whether such treatment may
esult in improved prognosis.
The second important aspect of this article relates to the
ethodology used for assessing aortic stiffness. Although
arotid femoral PWV is considered the “gold standard” for
ssessing arterial stiffness, measuring the exact distance
etween the flow-probe position at the carotid and femoral
evel may be difficult especially in obese men or women with
arge chest size. In contrast, CMR provides the advantage of
llowing exact distance measurements in the 3-dimensional
pace. Thus, PWV measured from the time delay of aortic
ow between the ascending to the descending aorta can be
ssessed very precisely using CMR. In addition, the method
s highly reproducible as elegantly shown by Boonyasirinant
t al. (8). Although in HCM patients CMR has proven
uperior to echocardiography in the accurate characteriza-
ion of the distribution of left ventricular hypertrophy (12),
he most significant advantage of CMR over other imaging
odalities may be attributed to the fact that it allows
ssessment of different morphological and functional pa-
ameters in 1 single imaging session including cine imaging,
erfusion, and delayed enhancement imaging as well as flow
easurements. Thus, CMR may currently be the onlymaging technique providing a fully comprehensive nonin-
K
casive evaluation of cardiovascular pathophysiology in
CM patients in one single step. In addition, CMR
rovides unique information on tissue characteristics not
btainable by any other imaging modality. This highlights
he outstanding importance of CMR imaging for the
omplete characterization of complex cardiovascular disease.
In summary, the paper by Boonyasirinant et al. (8) is
mportant because it gives us new insights into the complex
athophysiology of HCM that, apart from being a cardiac
isease, may also affect the vascular system. This paper reminds
s to broaden our view, which may sometimes be too focused
n the heart. We should learn from this paper that in order to
etter understand cardiac disease we need to look at both the
eart and vasculature. CMR is an exceptional and unique
maging modality to support us in this regard.
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